US Patent Application for PDCD1 Knockout RNA Molecule
Summary
The USPTO has published a new patent application (US20260085331A1) for an RNA molecule designed for biallelic knockout of PDCD1. The application, filed on September 18, 2023, details compositions comprising RNA molecules with specific guide sequences and their methods of use.
What changed
This document is a publication of a United States patent application (US20260085331A1) filed by Rafi Emmanuel concerning compositions and methods for biallelic knockout of PDCD1 using RNA molecules. The abstract describes RNA molecules with guide sequences and their uses, referencing specific sequence identifiers (SEQ ID NOs: 1-6220).
This publication represents a new intellectual property filing and does not impose immediate regulatory obligations on entities. However, it may be relevant for companies involved in gene editing, immunotherapy, or pharmaceutical research and development, particularly those working with PDCD1 targets. Compliance officers in these sectors should note this filing for potential future licensing or competitive landscape analysis.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Biallelic Knockout of PDCD1
Application US20260085331A1 Kind: A1 Mar 26, 2026
Inventors
Rafi EMMANUEL
Abstract
Compositions comprising an RNA molecule comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-6220 and methods and uses thereof.
CPC Classifications
C12N 15/907 C12N 9/226 C12N 15/11 C12N 2310/20 C12N 2800/80
Filing Date
2023-09-18
Application No.
19113031
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.